Wegovy (Semaglutide): Uses, Dosing, Side Effects, and Safety

Wegovy is a prescription medicine that contains semaglutide, the same active ingredient found in Ozempic and Rybelsus. Unlike those two, Wegovy is approved for weight management and for lowering heart risk in adults who have obesity or overweight. It now comes as a weekly injection and as a daily tablet. This guide explains what the current U.S. label says about uses, dosing patterns, side effects, and safety, so you can have a better conversation with your prescriber.

The facts below come mainly from the current Wegovy prescribing information on the FDA website (revised June 2026). Labels change, so check the newest version and the leaflet that comes with your medicine.

What Is Wegovy?

Wegovy is a brand-name medicine from Novo Nordisk. Semaglutide belongs to a group called GLP-1 receptor agonists. GLP-1 (glucagon-like peptide-1) is a natural hormone that helps regulate appetite and blood sugar. Semaglutide copies that hormone but lasts much longer in the body. The label gives its half-life as about one week.

Doctors prescribe Wegovy, and a pharmacy dispenses it. You cannot buy it over the counter. The label describes it as a treatment used together with a reduced-calorie diet and more physical activity. It does not replace those habits.

Wegovy Injection and Wegovy Tablets

The Wegovy label covers two forms:

• Injection. You inject it under the skin once a week. It comes as single-dose pens, single-dose syringes, and a multi-dose pen called Wegovy FlexTouch. A higher-strength single-dose pen, Wegovy HD (7.2 mg), also exists.
• Tablets. You swallow one tablet once a day. Strengths are 1.5 mg, 4 mg, 9 mg, and 25 mg.

The two forms have different instructions, so do not assume that advice for one applies to the other.

What Is Wegovy Used For?

The label lists these approved uses, always together with a reduced-calorie diet and increased physical activity:

• Heart protection. Both forms lower the risk of major cardiovascular events (cardiovascular death, non-fatal heart attack, or non-fatal stroke) in adults with established cardiovascular disease and either obesity or overweight.
• Weight reduction. Both forms help adults with obesity, or adults with overweight and at least one weight-related condition, reduce excess body weight and keep it off. The injection is also approved for children and teens aged 12 and older with obesity. The tablets are not established for children.
• Liver disease (injection only). The injection treats adults with noncirrhotic metabolic dysfunction-associated steatohepatitis (MASH), formerly called NASH, with moderate to advanced liver fibrosis. The FDA granted this use under accelerated approval, which means continued approval may depend on further trial results.

The label says not to use Wegovy together with other semaglutide products or any other GLP-1 medicine. That rule matters because Ozempic, Rybelsus, and similar drugs also contain GLP-1 agents.

How Much Weight Do People Lose?

Trial results show averages, not guarantees. In a 68-week trial of adults with obesity or overweight (without diabetes), people on the 2.4 mg injection lost about 14.9% of their body weight, compared with 2.4% on placebo. In adults who also had type 2 diabetes, the figures were 9.6% versus 3.4%. The label notes that people with type 2 diabetes lost less weight than people without it. In a 64-week trial of the 25 mg tablet, the average loss was 13.6% versus 2.4% for placebo.

Your own result may differ. Your prescriber can explain what to expect and how to measure progress.

How Does Wegovy Work?

GLP-1 receptors exist in areas of the brain that help control appetite and calorie intake. Semaglutide activates them. The label states that the drug lowers body weight, with more fat loss than lean mass loss, and that it likely works by affecting appetite. It also stimulates insulin release and reduces glucagon (a hormone that raises blood sugar) when blood sugar is high. In addition, it slows how quickly the stomach empties, which explains many digestive side effects.

The label says the exact way semaglutide lowers heart risk has not been established.

How to Use Wegovy Safely

Dosing Basics for the Injection

Your prescriber sets your dose. For general understanding, the label describes this pattern:

• Start at 0.25 mg once weekly for 4 weeks.
• Increase every 4 weeks: 0.5 mg, then 1 mg, then 1.7 mg.
• For adults, the usual maintenance dose is 2.4 mg (recommended) or 1.7 mg once weekly. For children aged 12 and older, it is also 2.4 mg or 1.7 mg.
• Adults who tolerate 2.4 mg for at least 4 weeks and need more weight reduction may move up to 7.2 mg once weekly.
• If you do not tolerate a step, the label says your prescriber may delay the next increase by 4 weeks.

You may inject at any time of day, with or without food, on the same day each week. You can change the day or the injection site without changing your dose. Inject into the abdomen, thigh, or upper arm, and rotate sites. The liquid should look clear and colorless.

Dosing Basics for the Tablets

• Start at 1.5 mg once daily for 30 days. The dose then rises every 30 days to 4 mg, then 9 mg, and then to the 25 mg maintenance dose from day 91.
• Take one tablet in the morning on an empty stomach with up to 4 ounces of plain water. Do not use other liquids.
• Swallow the tablet whole. Do not split, crush, or chew it.
• Wait at least 30 minutes before you eat, drink, or take other oral medicines.
• Do not take more than one tablet a day.

If you cannot tolerate the 25 mg tablet, the label says your prescriber may consider switching you to the 1.7 mg injection. Never switch forms on your own.

What to Do If You Miss a Dose

Injection. If the next scheduled dose is more than 2 days away, take the missed dose as soon as possible. If the next dose is less than 2 days away, skip the missed dose and resume on your usual day. If you miss two or more weekly doses in a row, the label says your prescriber should restart the dose increases at a lower dose to reduce stomach side effects.

Tablets. Skip the missed dose and take the next tablet the following day.

Common Side Effects of Wegovy

Digestive problems are the most common. In trials in adults with obesity or overweight, these side effects happened more often with the 2.4 mg injection than with placebo:

The label says digestive reactions were most common during dose increases, and the tablet trial showed a similar pattern. About 6.8% of people on the injection stopped treatment because of side effects, compared with 3.2% on placebo.

Other effects include hair loss (3.3% with 2.4 mg versus 1% with placebo; the label links it to weight loss) and dysesthesia, which means unusual skin sensations such as burning, tingling, or sensitivity. Dysesthesia rose with higher doses: 22% at 7.2 mg, 6% at 2.4 mg, and under 1% with placebo. Resting heart rate rose by an average of 1 to 4 beats per minute.

Serious Side Effects and Warnings

Boxed Warning: Thyroid C-Cell Tumors

Wegovy carries the FDA’s strongest warning. In rodents, semaglutide caused thyroid C-cell tumors. Researchers do not know whether it causes these tumors, including a rare cancer called medullary thyroid carcinoma (MTC), in humans. Do not use Wegovy if you or a family member has had MTC, or if you have Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). Report a neck lump, trouble swallowing, shortness of breath, or lasting hoarseness.

Other Important Warnings

• Pancreatitis. Persistent, severe stomach pain, sometimes spreading to the back, needs prompt medical attention. The label says to stop Wegovy if pancreatitis is suspected.
• Gallbladder disease. Gallstones and gallbladder inflammation occurred more often with Wegovy, even after accounting for weight loss. Rates were higher in teens than in adults.
• Low blood sugar. Risk rises in people with type 2 diabetes, especially if they also use insulin or a sulfonylurea. Doctors may lower those doses.
• Kidney injury. Vomiting and diarrhea can cause dehydration, which can injure the kidneys. Some cases needed dialysis.
• Severe digestive reactions. Severe reactions affected 4.1% of injection users versus 0.9% on placebo. The label does not recommend Wegovy for people with severe gastroparesis (very slow stomach emptying).
• Allergic reactions. Anaphylaxis and angioedema (swelling of the face, lips, or tongue) have been reported. Stop the medicine and seek urgent care.
• Diabetic eye disease. People with type 2 diabetes and a history of retinopathy need monitoring. Report vision changes.
• Heart rate. Tell your prescriber about a racing or pounding heartbeat at rest. The label says to stop Wegovy if a resting heart rate increase continues.
• Anesthesia. Slower stomach emptying can leave food in the stomach even after fasting, and stomach contents can enter the lungs during anesthesia or deep sedation. Tell every surgeon, dentist, and anesthesia provider that you take Wegovy.

The label also lists other findings from trials, including low blood pressure and fainting, appendicitis, and more hip and pelvis fractures in women and in people aged 75 and older in one heart trial. After the drug launched, people reported bowel blockage and severe constipation.

Who Should Avoid Wegovy or Use Caution?

Do not use Wegovy if you have a personal or family history of MTC, if you have MEN 2, or if you have had a serious allergic reaction to semaglutide or any ingredient in the product. Tell your prescriber before you start if you have pancreas or gallbladder problems, kidney disease, diabetes (especially with eye disease), severe stomach or digestion problems, or a planned surgery or procedure that uses anesthesia or deep sedation.

The injection is approved for teens aged 12 and older with obesity, though teens had more gallstones, gallbladder inflammation, low blood pressure, rash, and hives than adults. The label found no overall difference in effectiveness in adults 65 and older, but adults 75 and older reported more serious side effects overall in one trial.

Wegovy Drug Interactions

Because Wegovy slows stomach emptying, it can change how quickly some pills are absorbed. In studies of the injection, semaglutide did not affect absorption of oral medicines tested. In a study with the tablet, levothyroxine (a thyroid hormone medicine) exposure rose by 33%. The label advises extra monitoring for oral medicines that have a narrow safety margin or need regular monitoring.

Insulin and sulfonylurea diabetes medicines raise the risk of low blood sugar when combined with Wegovy. Do not combine Wegovy with other semaglutide products or other GLP-1 medicines. Give your pharmacist a full list of your prescriptions, over-the-counter medicines, vitamins, and supplements.

Pregnancy and Breastfeeding

Pregnancy. The label says Wegovy may cause fetal harm and that weight loss offers no benefit during pregnancy. If you use it for weight reduction or heart risk, stop when pregnancy is recognized, and stop at least 2 months before a planned pregnancy because semaglutide leaves the body slowly. A pregnancy exposure registry exists for people who become pregnant while taking it. For MASH, the label says to use it in pregnancy only if the potential benefit justifies the risk.

Breastfeeding. The label says breastfeeding is not recommended with Wegovy tablets because a tablet ingredient (SNAC) or its by-products can pass into milk. For the injection, no data exist on milk transfer, so weigh the benefits of breastfeeding against your treatment needs with your provider.

Storage and Handling

Storage rules differ by product: pens, syringes, FlexTouch, and tablets. Follow the carton and the Instructions for Use that come with your specific product, and ask your pharmacist if anything is unclear. Never share a Wegovy FlexTouch pen with anyone, even if you change the needle, because sharing can pass on blood-borne infections.

Counterfeit and Compounded Semaglutide

Because demand is high, look-alike products circulate. The FDA warns that compounded GLP-1 drugs are not FDA approved and that it has received reports of dosing errors, side effects, and fraudulent products. It is also aware of counterfeit versions of related brand-name products. Use only prescriptions from licensed pharmacies, and report suspicious products to the pharmacist and to the FDA’s MedWatch program.

When to Get Medical Help

Call 911 or go to an emergency room for trouble breathing or swelling of the face, lips, or tongue. Contact your healthcare provider promptly for severe or lasting stomach pain, repeated vomiting or diarrhea, signs of dehydration, a neck lump, vision changes, a racing heartbeat at rest, or signs of low blood sugar such as shakiness, sweating, and confusion. In case of an overdose, call Poison Help at 1-800-222-1222.

Frequently Asked Questions About Wegovy

Is Wegovy the same as Ozempic?

Both contain semaglutide, but they are separate products with different approved uses and doses. Wegovy is approved for weight management and heart risk reduction. Ozempic is approved for type 2 diabetes. Do not use them together.

Can I take Wegovy as a pill?

Yes. The current label includes Wegovy tablets for adults. The tablet follows a daily schedule with strict rules about empty stomach, water, and a 30-minute wait.

Is Wegovy safe for teenagers?

The injection is approved for people aged 12 and older with obesity. The tablets, the 7.2 mg dose, and the MASH use are not established for children. A pediatric specialist should guide treatment.

What happens if I stop Wegovy?

Talk with your prescriber first. The label says semaglutide stays in the body for about 5 to 7 weeks after the last dose, and the label describes the product as a long-term weight maintenance treatment. Your prescriber can discuss what to expect.

Does Wegovy cause hair loss?

Hair loss was reported more often with Wegovy than placebo, and the label associates it with weight reduction. Tell your prescriber if it bothers you.

Can I use Wegovy with insulin?

The label says the combination has not been evaluated in type 1 diabetes or with insulin in some trials, and low blood sugar becomes more likely. Your prescriber may adjust insulin doses.

References

• Wegovy (semaglutide) prescribing information, U.S. FDA (revised 06/2026)
• GLP-1 agonists, MedlinePlus Medical Encyclopedia
• FDA’s Concerns with Unapproved GLP-1 Drugs Used for Weight Loss

Conclusion

Wegovy is a semaglutide medicine for long-term weight management and heart risk reduction in adults with obesity or overweight, with an injection also approved for teens and for certain liver disease. It can produce meaningful weight loss, but it carries a boxed warning and real risks, including digestive problems, gallbladder disease, pancreatitis, and dehydration. Follow your prescriber’s plan, report symptoms that do not ease, tell every care provider before a procedure, and buy only genuine product from a licensed pharmacy.

Medical Disclaimer

Disclaimer: This article is for informational purposes only and does not constitute medical advice, diagnosis, or treatment. The information provided is not a substitute for professional medical advice from a qualified healthcare provider. Always consult your doctor or pharmacist before starting, stopping, or changing any medication. Do not disregard professional medical advice or delay seeking it because of information in this article. If you think you are experiencing a medical emergency, seek emergency medical assistance immediately.